Stockreport

Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF - Trial to Use “Process B” RP-L102, Which Incorporates Higher Cell Doses, Transduction Enhancers, and Commercial-grade Vector Manufacturing and Cell Proc [Read more]